Personalised medicine to relieve the health service
Smaller patient groups and targeted treatments are the future of cancer care in Norway.
HealthCatalyst will support Norwegian companies with advice, networks and activities to strengthen their position in the German healthcare market, as a part of the government's export reform.
HealthCatalyst AS is a non profit organisation owned with equal parts by Norwegian Smart Care Cluster, Oslo Cancer Cluster and Norway Health Tech. Visit the website here: https://www.healthcatalyst.no
Nov 4, 2024
Sofia Linden
HealthCatalyst, which consists of Norway Health Tech, Oslo Cancer Cluster, Smart Care Cluster and The Life Science Cluster, has been selected to drive the Norwegian government's health initiative in Germany under the export reform “Hele Norge eksporterer”. Germany has been identified as a key market for Norwegian health companies wishing to increase their exports, and the project will have a special focus on companies with existing export revenues that want to expand their market share.
In collaboration with Innovation Norway and Team Norway in Germany, Health Catalyst will offer:
📌Advice on market barriers such as pricing models, reimbursement schemes and regulatory requirements, as well as access to relevant competence environments and partners.
📌Targeted events for Norwegian companies at key trade fairs, such as DMEA in Berlin, to strengthen their visibility and network in the German market.
📌Investor program in collaboration with foreign investors and the Nordic ecosystem, which can contribute to growth capital and increased international visibility.
In addition, HealthCatalyst will carry out a “digital bundling” of healthcare services across the Nordic region and Germany, where several digital products and services can be “bundled” to create holistic solutions adapted to the healthcare market.
This article was originally published in Norwegian on the Norwegian Smart Care Cluster's website.
Smaller patient groups and targeted treatments are the future of cancer care in Norway.
Geir Hetland, Chief Financial Officer of Thermo Fisher Scientific, is the latest addition to the board of Oslo Cancer Cluster.